查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1525326

全球碘缺乏藥物市場規模研究，按劑型（片劑、其他）、配銷通路（醫院藥房、藥房和零售藥房、線上提供者）以及 2022-2032 年區域預測

Global Iodine Deficiency Drug Market Size study, by Dosage Form (Tablets, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers), and Regional Forecasts 2022-2032
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 285 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球缺碘藥物市場價值約為41.4億美元，預計在2024-2032年預測期內將以超過5.76%的健康成長率成長。碘缺乏症（IDD）是全球重大的公共衛生問題，原因是飲食中碘攝取不足，導致甲狀腺激素產生不足。這種被稱為甲狀腺功能減退症的缺陷可能會影響所有年齡、性別和種族的人，但在各國 60 歲以上的女性和兒童中尤其普遍。製藥公司正在積極致力於左旋甲狀腺素藥物的開發和批准，以滿足不斷成長的需求，特別是在醫療基礎設施低度開發的地區。例如，2021年，Zydus Cadila宣布其治療甲狀腺功能低下的甲狀腺藥物已獲得美國FDA批准。

全球甲狀腺功能減退症盛行率的不斷上升是推動市場對缺碘藥物需求的關鍵驅動力。甲狀腺功能減退症的特徵是甲狀腺激素分泌不足，通常是由於碘缺乏造成的，特別是在碘鹽攝取不足的地區。隨著人們越來越認知到碘對甲狀腺功能的重要性，醫療保健提供者正在診斷更多的甲狀腺功能減退症病例，從而增加了對碘補充療法的需求。各國政府和衛生組織也正在實施解決碘缺乏問題的計劃，進一步刺激市場成長。製藥公司正在針對不同患者人口統計和地區需求推出創新的碘補充劑配方和劑型。這個促進因素強調了碘缺乏藥物在治療甲狀腺疾病中的關鍵作用，並強調了它們在全球公共衛生策略中日益重要的作用。然而，與左旋甲狀腺素相關的副作用，例如不規則心悸，以及懷孕期間和心臟病患者定期血液檢查的需要，限制了市場的成長。

全球缺碘藥物市場的主要區域包括北美、歐洲、亞太地區、拉丁美洲、中東和非洲。 2023年，歐洲在收入方面主導全球缺碘藥物市場，預計在2024-2032年預測期內成長最快。這是由於嚴格的公共衛生措施、廣泛的碘鹽計劃以及對甲狀腺疾病的高度認知。該地區各國優先考慮補充碘，以防止缺乏碘，導致甲狀腺相關健康問題，如甲狀腺功能減退和甲狀腺腫。歐洲的製藥公司專注於開發適合不同人群需求的有效碘補充劑。該地區在醫療基礎設施和研究方面採取的積極主動的做法促進了持續創新，並確保了高標準的碘缺乏管理。這一領導地位鞏固了歐洲在塑造全球碘缺乏藥物市場的關鍵作用。

在全球碘缺乏藥物市場中營運的主要公司包括

雅培實驗室

艾伯維公司

西普拉有限公司

費森尤斯股份公司 (Fresenius Kabi)

葛蘭素史克

羽扇豆

麥克勞茲製藥公司

默克公司

輝瑞公司

梯瓦製藥工業股份有限公司

目錄

第 1 章：全球碘缺乏藥物市場執行摘要

  • 全球碘缺乏藥物市場規模及預測（2022-2032）
  • 區域概要
  • 分部摘要
    • 依劑型分類
    • 按配銷通路
  • 主要趨勢
  • 經濟衰退的影響
  • 分析師推薦與結論

第 2 章：全球碘缺乏藥物市場定義與研究假設

  • 研究目的
  • 市場定義
  • 研究假設
    • 包含與排除
    • 限制
    • 供給側分析
      • 可用性
      • 基礎設施
      • 監管環境
      • 市場競爭
      • 經濟可行性（消費者的角度）
    • 需求面分析
      • 監理框架
      • 技術進步
      • 環境考慮
      • 消費者意識和接受度
  • 估算方法
  • 研究涵蓋的年份
  • 貨幣兌換率

第3章：全球碘缺乏藥物市場動態

  • 市場促進因素
    • 甲狀腺功能低下症盛行率增加
    • 教育和意識計劃
    • 兒童甲狀腺功能低下症增加
  • 市場挑戰
    • 左旋甲狀腺素的副作用
    • 需要定期驗血
  • 市場機會
    • 發展中地區的製藥業興趣
    • 研發投資

第 4 章：全球碘缺乏藥物市場產業分析

  • 波特的五力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭競爭
    • 波特五力模型的未來方法
    • 波特的五力影響分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會的
    • 技術性
    • 環境的
    • 合法的
  • 頂級投資機會
  • 最佳制勝策略
  • 顛覆性趨勢
  • 產業專家視角
  • 分析師推薦與結論

第 5 章：全球碘缺乏藥物市場規模與預測：按劑型 - 2022-2032

  • 細分儀表板
  • 全球缺碘藥物市場：劑型收入趨勢分析，2022 年和 2032 年
    • 平板電腦
    • 其他

第 6 章：全球碘缺乏藥物市場規模與預測：按配銷通路- 2022-2032

  • 細分儀表板
  • 全球缺碘藥物市場：2022 年和 2032 年配銷通路收入趨勢分析
    • 醫院藥房
    • 藥局和零售藥局
    • 線上提供者

第 7 章：全球碘缺乏藥物市場規模及預測：按地區 - 2022-2032

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 中東和非洲其他地區

第 8 章：競爭情報

  • 重點企業SWOT分析
  • 頂級市場策略
  • 公司簡介
    • Abbott Laboratories
      • 關鍵訊息
      • 概述
      • 財務（視數據可用性而定）
      • 產品概要
      • 市場策略
    • AbbVie Inc.
    • Cipla Ltd.
    • Fresenius SE & Co. KGaA (Fresenius Kabi)
    • GlaxoSmithKline
    • Lupin
    • Macleods Pharmaceuticals
    • Merck KGaA
    • Pfizer
    • Teva Pharmaceutical Industries Ltd., Inc.

第 9 章：研究過程

  • 研究過程
    • 資料探勘
    • 分析
    • 市場預測
    • 驗證
    • 出版
  • 研究屬性
簡介目錄

The Global Iodine Deficiency Drug Market is valued approximately at USD 4.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.76% over the forecast period 2024-2032. Iodine Deficiency Disorders (IDD) represent a significant public health issue globally, resulting from inadequate dietary intake of iodine, which leads to insufficient thyroid hormone production. This deficiency, known as hypothyroidism, can affect individuals of all ages, genders, and ethnicities, though it is particularly prevalent among women over the age of 60 and children in various countries. Pharmaceutical companies are actively focusing on the development and approval of levothyroxine drugs to meet the increasing demand, particularly in regions with underdeveloped healthcare infrastructure. For instance, in 2021, Zydus Cadila announced that it has received U.S. FDA approval for its thyroid drug for hypothyroidism.

The increasing prevalence of hypothyroidism globally is a key driver propelling the demand for iodine deficiency drugs in the market. Hypothyroidism, characterized by insufficient thyroid hormone production, often results from iodine deficiency, especially in regions where iodized salt intake is inadequate. As awareness grows about the importance of iodine in thyroid function, healthcare providers are diagnosing more cases of hypothyroidism, thereby boosting the need for iodine supplementation therapies. Governments and health organizations are also implementing programs to address iodine deficiency, further stimulating market growth. Pharmaceutical companies are responding with innovative formulations and dosage forms of iodine supplements tailored to different patient demographics and regional needs. This driver underscores the critical role of iodine deficiency drugs in managing thyroid disorders and highlights their increasing importance in public health strategies worldwide. However, side effects associated with levothyroxine, such as irregular heart palpitations, and the need for regular blood tests during pregnancy and in heart patients restrain market growth.

The key region in the Global Iodine Deficiency Drugs Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, the Europe dominates the Global Iodine Deficiency Drugs Market in terms of revenue and expected to grow fastest during the forecast period 2024-2032. This is due to stringent public health measures, widespread iodized salt programs, and high awareness of thyroid disorders. Countries across the region prioritize iodine supplementation to prevent deficiencies, which contribute to thyroid-related health issues like hypothyroidism and goiter. Pharmaceutical companies in Europe focus on developing effective iodine supplements tailored to diverse population needs. The region's proactive approach in healthcare infrastructure and research fosters continuous innovation and ensures high standards of iodine deficiency management. This leadership solidifies Europe's pivotal role in shaping the global market for iodine deficiency drugs.

Major companies operating in the Global Iodine Deficiency Drug Market include

Abbott Laboratories

AbbVie Inc.

Cipla Ltd.

Fresenius SE & Co. KGaA (Fresenius Kabi)

GlaxoSmithKline

Lupin

Macleods Pharmaceuticals

Merck KGaA

Pfizer

Teva Pharmaceutical Industries Ltd., Inc.

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Iodine Deficiency Drug Market Executive Summary

  • 1.1. Global Iodine Deficiency Drug Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Dosage Form
    • 1.3.2. By Distribution Channel
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Iodine Deficiency Drug Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Iodine Deficiency Drug Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increase in Prevalence of Hypothyroidism
    • 3.1.2. Education and Awareness Programs
    • 3.1.3. Increase in Hypothyroidism in Children
  • 3.2. Market Challenges
    • 3.2.1. Side Effects of Levothyroxine
    • 3.2.2. Need for Regular Blood Tests
  • 3.3. Market Opportunities
    • 3.3.1. Pharmaceutical Interest in Developing Regions
    • 3.3.2. R&D Investments

Chapter 4. Global Iodine Deficiency Drug Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunity
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Iodine Deficiency Drug Market Size & Forecasts by Dosage Form 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Iodine Deficiency Drug Market: Dosage Form Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Tablets
    • 5.2.2. Others

Chapter 6. Global Iodine Deficiency Drug Market Size & Forecasts by Distribution Channel 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Iodine Deficiency Drug Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Drug Stores and Retail Pharmacies
    • 6.2.3. Online Providers

Chapter 7. Global Iodine Deficiency Drug Market Size & Forecasts by Region 2022-2032

  • 7.1. North America Iodine Deficiency Drug Market
    • 7.1.1. U.S. Iodine Deficiency Drug Market
      • 7.1.1.1. Dosage Form breakdown size & forecasts, 2022-2032
      • 7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
    • 7.1.2. Canada Iodine Deficiency Drug Market
  • 7.2. Europe Iodine Deficiency Drug Market
    • 7.2.1. U.K. Iodine Deficiency Drug Market
    • 7.2.2. Germany Iodine Deficiency Drug Market
    • 7.2.3. France Iodine Deficiency Drug Market
    • 7.2.4. Spain Iodine Deficiency Drug Market
    • 7.2.5. Italy Iodine Deficiency Drug Market
    • 7.2.6. Rest of Europe Iodine Deficiency Drug Market
  • 7.3. Asia-Pacific Iodine Deficiency Drug Market
    • 7.3.1. China Iodine Deficiency Drug Market
    • 7.3.2. India Iodine Deficiency Drug Market
    • 7.3.3. Japan Iodine Deficiency Drug Market
    • 7.3.4. Australia Iodine Deficiency Drug Market
    • 7.3.5. South Korea Iodine Deficiency Drug Market
    • 7.3.6. Rest of Asia Pacific Iodine Deficiency Drug Market
  • 7.4. Latin America Iodine Deficiency Drug Market
    • 7.4.1. Brazil Iodine Deficiency Drug Market
    • 7.4.2. Mexico Iodine Deficiency Drug Market
    • 7.4.3. Rest of Latin America Iodine Deficiency Drug Market
  • 7.5. Middle East & Africa Iodine Deficiency Drug Market
    • 7.5.1. Saudi Arabia Iodine Deficiency Drug Market
    • 7.5.2. South Africa Iodine Deficiency Drug Market
    • 7.5.3. Rest of Middle East & Africa Iodine Deficiency Drug Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Abbott Laboratories
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Market Strategies
    • 8.3.2. AbbVie Inc.
    • 8.3.3. Cipla Ltd.
    • 8.3.4. Fresenius SE & Co. KGaA (Fresenius Kabi)
    • 8.3.5. GlaxoSmithKline
    • 8.3.6. Lupin
    • 8.3.7. Macleods Pharmaceuticals
    • 8.3.8. Merck KGaA
    • 8.3.9. Pfizer
    • 8.3.10. Teva Pharmaceutical Industries Ltd., Inc.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes